Abstracts tagged "registry"

Abstract Number: 1760 • 2014 ACR/ARHP Annual Meeting
United Kingdom & Ireland Vasculitis Registry – Cross-Sectional Data on the First 1085 Patients
Jan Sznajd^1,2, Alan D. Salama³, David Jayne⁴, Afzal Chaudhry⁵, Michael Robson⁶, Joe Rosa², Neil Basu⁷, Sarah Moran⁸, Michael Venning⁹, Peter Lanyon¹⁰, Asheesh Sharma¹¹, Mark A. Little¹², Richard Watts¹³ and Raashid Luqmani¹⁴, ¹Jagiellonian University Medical College, Krakow, Poland, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Centre for Nephrology, University College London, London, United Kingdom, ⁴Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁵Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶King’s College London, London, United Kingdom, ⁷Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ⁸Cork University Hospital, Cork, United Kingdom, ⁹Manchester Royal Infirmary, Manchester, United Kingdom, ¹⁰Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹¹University Hospital Aintree Liverpool, Liverpool, United Kingdom, ¹²Trinity College Dublin, Dublin, Ireland, ¹³Department of Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom, ¹⁴Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom
Background/Purpose Clinical care and research into systemic vasculitis is hampered by its rarity and its presentation to a wide array of medical specialties. We aimed…
Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
Kenneth G. Saag¹, Kevin L. Winthrop², Daniel E. Furst³, Kimberly Alexander⁴, Angelika Jahreis⁵, Carol Chung⁶ and Kurt Oelke⁷, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³University of California at Los Angeles, Los Angeles, CA, ⁴Epidemiology, Genentech, Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Genentech, Inc, South San Francisco, CA, ⁷Rheumatic Disease Center, Glendale, WI
Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…
Abstract Number: 853 • 2014 ACR/ARHP Annual Meeting
Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis – a Study from the ARTIS and Danbio Registers
Johan Askling¹, Lene Dreyer², Merete Lund Hetland³, Lennart Jacobsson⁴, Lars-Erik Kristensen⁵, Bente Glintborg⁶, . ARTIS and DANBIO study groups⁷ and Karin Hellgren⁸, ¹Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²Gentofte University Hospital, Hellreup, Denmark, ³Glostrup University Hospital, Glostrup, Denmark, ⁴Sahlgrenska Academy, Gothenburg, Sweden, ⁵Lund University, Lund, Sweden, ⁶Gentofte University Hospital, Gentofte, Denmark, ⁷Karolinska Institutet, stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden
Background/Purpose Most studies of the safety profile of TNF inhibitors (TNFi) - in particular in relation to cancer risks - have been performed in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].